Clinical Trial Update: A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects [Phase 1]

View source ↗

Summary

Phase I pharmacokinetic study in healthy Chinese subjects evaluating single and repeat doses of the inhaled triple therapy Fluticasone furoate / umeclidinium br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED